FDA Approves Over-the-Counter Sale of Powerful Acne Gel Differin Epiduo
The U.S. Food and Drug Administration (FDA) has authorized the over-the-counter sale of the combination drug (adapalene + benzoyl peroxide) for individuals aged 12 and older, expanding access to dermatological therapy.
This is an analytical first-person article written from the perspective of an insider working at the intersection of dermatology business, regulatory affairs, and strategic marketing.
Title: Countdown for Benzoyl Peroxide and a Closed Door for Generics: Why the FDA Approved the OTC Switch for Differin Epiduo Only Now
Introduction: One Winner, Three Losers
On May 23, 2026, the FDA officially approved the switch of the combination gel Differin Epiduo (adapalene 0.1% + benzoyl peroxide 2.5%) to over-the-counter status for individuals aged 12 and older. Media headlines read: "Dermatology bestseller now available without a prescription," "Millions of acne patients gain easy access." It sounds like a win for consumers.
As an analyst who has tracked Galderma's and its competitors' portfolio strategies for ten years, I see a very different picture. This decision is not altruism or a drive to expand access. It is a forced move driven by three things: an expiring patent, an overheated telemedicine market, and a desire to "close" the U.S. market to generics before they can emerge.
The most important point that all news outlets are missing: the exact same combination of active ingredients (adapalene + benzoyl peroxide) has been produced and sold in the U.S. as a prescription generic since 2023. Now, in May 2026, Galderma has achieved what no generic manufacturer could—securing exclusive OTC status for a combination that is essentially old and well-studied.
Non-Obvious Insight (What Press Releases Don't Say):
Galderma is not just switching a drug to OTC. They are reshaping the market to kill two birds with one stone.
The first bird is telemedicine services like Curology, Hims & Hers, and Nurx. Over the past five years, these companies have built a billion-dollar business by prescribing combination acne drugs (including adapalene + benzoyl peroxide) through remote consultations for $25–50 per "prescription." Now that any patient can buy Epiduo at Walmart or Amazon without a prescription, the economic model of these services collapses. Their "unique value proposition" disappears overnight.
The second bird is the regulatory barrier. The FDA requires a massive amount of data on safety for self-administration for OTC drugs. Galderma spent years and millions of dollars on these studies. Now, any generic manufacturer that wants to launch its own "adapalene + benzoyl peroxide" OTC product must repeat this entire process from scratch—conduct its own clinical trials under the OTC protocol, costing tens of millions and taking 3–5 years. Galderma has created a "legal monopoly" for the next 3–5 years.
1. [The Core]: Why the Switch Happened Now, Not Five Years Ago
Background: Adapalene (alone) switched to OTC in 2016. Since then, millions of Americans have treated acne with adapalene alone, even though the American Academy of Dermatology's clinical guidelines since 2021 clearly state: the combination of retinoid + benzoyl peroxide is first-line therapy, working significantly better than each component alone.
Why did Galderma wait ten years? The answer lies in money and fear of cannibalization.
Epiduo (prescription version) provided Galderma with steady revenue from dermatologist visits. Switching it to OTC meant losing control over price and sales channels. But in 2024–2025, two events changed the calculations:
- Patent expiration for adapalene in several jurisdictions. Generic manufacturers had already started producing their own versions of "adapalene + benzoyl peroxide" in some countries. The best defense is to move to OTC in the largest market (the U.S.), where generics cannot follow without huge costs.
- Rising popularity of "personalized" dermatology services. Hims & Hers reported a 40% year-over-year revenue increase in its dermatology segment in 2025, largely driven by "customized combinations" for acne. Galderma realized it was losing market share not to competing brands but to services that aggregate prescriptions. OTC status is a way to "cut out the middleman."
2. Timeline and Context: Numbers That Didn't Make It to Press Releases
Official data Galderma cited to support the switch:
- 15 years of dermatologist use, millions of prescriptions worldwide.
- Over 10 Galderma-sponsored studies involving more than 3,200 patients.
- Clinically significant improvement as early as week 1, antimicrobial activity from day 1.
- 70.3% reduction in inflammatory acne lesions by week 12.
- Sustained reduction of approximately 65% over 12 months.
But what aren't they saying?
Adapalene is the third retinoid, but not the strongest. Tretinoin (retinoic acid) and tazarotene have more pronounced effects on photoaging and severe acne. However, tretinoin will never go OTC due to teratogenicity and risk of severe irritation. Galderma chose adapalene precisely because it is the safest of the retinoids—minimal risk for pregnant women (Category C, unlike tretinoin which is Category D), minimal irritation.
This is not a choice of the "most effective" drug. It is a choice of the "safest for OTC use."
3. Who Wins and Who Loses
- Winner (1): Galderma (SIX: GALD). The company's stock will likely get a short-term boost. Morgan Stanley analysts, in their May report on Galderma, had already factored this switch into their models, but the market may not have fully priced it in. Estimated additional market potential in the U.S. is about $300–400 million in annual revenue by 2028.
- Winner (2): Retail chains (Walmart, Target, Ulta, Amazon). A new category leader in the "cosmeceutical" segment with high margins. Launching in summer 2026 is perfect timing for the back-to-school season, when parents stock up on acne treatments before school.
- Winner (3): Teenagers and young adults with mild to moderate acne. They gain access to the dermatological standard of care without a doctor's visit, which in the U.S. costs an average of $150–250 without insurance.
- Loser (1): Telemedicine services (Curology, Hims & Hers, Apostrophe). Their "user experience" and "convenience" are no longer needed. Revenue from dermatology could drop by 20–30% within 12 months of the Epiduo OTC launch. Hims & Hers (NYSE: HIMS) already fell 4% after the news.
- Loser (2): Generic manufacturers (Teva, Perrigo, Taro). They cannot bring their combination generics to OTC due to the regulatory barrier. Their only channel is prescription, which will shrink as patients switch to the OTC version.
- Loser (3): Dermatologists who earned from acne consultations. The flow of patients with mild acne will dry up, freeing time for more complex cases (psoriasis, eczema, severe acne) but reducing the total number of paid visits.
4. What the Media Isn't Saying
- "Without a prescription" does not mean "cheap." Expected retail price is $30–45 per tube (similar to current Differin Gel). This is significantly cheaper than a dermatologist visit ($150+), but more expensive than generic prescriptions with insurance (many patients paid $10–20 copay). For the uninsured, it's a win. For the insured with low copays, it may be a loss.
- Systemic risk: patients with severe acne may not see a doctor. Self-administration of a strong combination can mask disease progression. Severe nodulocystic acne requires isotretinoin (Accutane)—a systemic drug with serious side effects. If a patient with severe acne uses Epiduo unsuccessfully for six months, they lose time and risk scarring. The FDA apparently deemed the risk low, but it exists.
- Geography matters. The press release specifically states: "Outside the U.S., Epiduo remains a prescription drug." This is a deliberate strategy—first "capture" the largest and most profitable market (U.S.), then, after 2–3 years, apply to Europe (EMA) with the same dossier. European regulators are significantly more conservative regarding OTC switches for retinoids.
- The benzoyl peroxide problem. This component is unstable and can degrade if stored improperly (high temperature, sunlight). In the prescription version, quality control was ensured by the pharmacy. In retail, not necessarily. Galderma claims their "Simulgel base" solves the issue. But on a real Walmart shelf in summer, I wouldn't be so sure.
5. Forecast: Next 30 Days and 90 Days
Next 30 Days (June 2026):
- Event X: Hims & Hers (HIMS) and Curology will issue emergency statements to investors. I expect them to announce accelerated launches of new "exclusive" formulas (e.g., adding clindamycin, which remains prescription, or switching to tretinoin + benzoyl peroxide). They will try to differentiate.
- J.P. Morgan analysts will revise Galderma's rating. The current stock price (around 70–75 Swiss francs, ticker GALD) could see an upgrade to 80–85 CHF by end of June.
Next 90 Days (August–September 2026):
- Sales launch (summer 2026). I expect a massive marketing campaign on TikTok and Instagram—budgets of $50–80 million in the first year. Dermatologist influencers will start "recommending" Epiduo (for paid integration).
- Key risk: FDA response to generic applications. Within 90 days of OTC approval, one of the major generic manufacturers (Teva, Perrigo, or Taro) may file a petition with the FDA to allow their own OTC generic on the grounds that the active ingredients are identical and already studied. The probability of success is less than 5%, but the mere filing creates uncertainty and could knock Galderma's stock down 5–7%.
- Impact on retail chains. I expect Walmart and Target to give Epiduo "premium shelf space" in the skincare segment, next to CeraVe and La Roche-Posay. This is a symbolic step: cosmeceuticals are finally blurring the line between pharmacy and mass market.
Verdict:
The FDA's decision on Differin Epiduo is not a revolution in dermatology (the drug is old and well-studied). It is a revolution in the business model of acne therapy. Galderma is shifting decision-making from the doctor to the consumer while simultaneously cutting off the oxygen to telemedicine middlemen.
If you are an investor—consider a long position in Galderma (SIX:GALD), but understand that the main revenue from this product will only start growing in 2027. If you are a consumer—great news: an effective treatment becomes more accessible. If you own a telemedicine startup—you urgently need to find a new business model.
And remember: 70.3% reduction in inflammation is from a clinical trial. In real life, with irregular application and missed days, it will be lower. But it's still better than nothing. And certainly better than paying $200 for a dermatologist visit to get the same thing prescribed.
— Editorial Team
